SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

The community is closely tracking the company's upcoming earnings report, with high anticipation for updates on its hyperscaler data center contracts and Small Modular Reactor (SMR) pipeline. Traders are broadly optimistic, citing strong institutional support and a robust backlog, while debates continue regarding the potential impact of geopolitical tensions on long-term performance.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares experienced significant volatility and a decline following strong earnings results, primarily driven by investor reaction to a pre-scheduled, multi-month stock-trading plan by Chairman Larry Ellison to sell 50 million shares. While some traders view the sell-off as an opportunity or mere market manipulation of options, others expressed concern over the company's high debt levels and aggressive capital expenditures for AI infrastructure.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending as investors monitor ongoing Middle East tensions and geopolitical conflicts, while reacting to a mix of macroeconomic data, including inflation reports and Federal Reserve commentary. Market participants remain focused on how these factors, alongside corporate earnings and shifts in interest rate expectations, are influencing market volatility.

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is currently trending due to investor anticipation surrounding the upcoming pivotal Q3 Phase 3 eGFR data readout for its flagship drug, Trutakna. The community sentiment remains highly bullish, centered on the belief that a positive data release will act as a major catalyst for a valuation re-rating and potential short squeeze given the stock's significant short interest and institutional backing.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to the announcement of a new $1 billion at-the-market equity offering program, which has sparked significant debate among traders regarding shareholder dilution and the company's financial strategy. While some investors remain optimistic about the long-term potential of the company's advanced nuclear energy pipeline, many are expressing frustration over continued share price declines and ongoing insider selling.

Nintendo Co., Ltd. engages in the development, manufacture, and sale of home entertainment products. Its entertainment products include portable and console game machines and software, trump cards and Karuta (Japanese-style playing cards), multinational consumer electronics, home console hardware such as Nintendo Wii, Nintendo DS, Nintendo 3DS, as well as software for handheld and home console gaming machines. The company was founded by Fusajiro Yamauchi on September 23, 1889 and is headquartered in Kyoto, Japan.

Nintendo Co. Ltd - ADR

The discussion surrounding Nintendo is primarily driven by investor frustration over the stock's persistent decline, which many attribute to rising memory chip costs and margin compression for the Switch 2 despite strong software demand. While some traders view the current price as an undervalued entry point supported by robust IP and upcoming movie releases, others are concerned about the stock's ongoing downward trend and its underperformance relative to broader market indexes.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased attention as traders discuss its post-quantum cryptography roadmap and technical upgrades, while others remain skeptical due to long-term price performance and foundation-led token supply dynamics. Sentiment is divided between long-term holders accumulating during a perceived consolidation phase and vocal critics expecting further downside.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending amid intense debate as traders react to its recent price action and recurring cycle of volatility, with many users expressing frustration over "greedy" bag holders who missed past opportunities to take profits. Discussion remains heavily polarized between those expecting further downside toward historical lows and others anticipating a long-term recovery.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as investors react to the newly announced partnership with AEG to develop a permanent vertiport in downtown Los Angeles. Discussion remains focused on this infrastructure milestone, the Boeing strategic deal, and ongoing debates regarding the timeline for piloted flight certification.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Shares of SELLAS Life Sciences are trading lower following a surge in volatility and negative social media sentiment, which traders attribute to a coordinated campaign of misinformation and panic-selling based on third-party statistical modeling. While long-term shareholders remain focused on the potential outcomes of the REGAL clinical trial and maintain conviction in the underlying science, the stock faces pressure from technical trading dynamics and increased uncertainty regarding the timeline for final trial data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’

Axsome Therapeutics is trending as investors react to a bullish outlook following positive key opinion leader discussions regarding the commercial potential of Auvelity for Alzheimer's disease agitation. Market sentiment is bolstered by multiple analyst price target increases and ongoing anticipation for the drug's launch trajectory in this new indication.

Equity

Citing Bloomberg Symphony figures for the 30-milligram starter dose used when doctors begin treatment, a Mizuho analyst said new prescriptions for Auvelity rose 32% from July to August. 


Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAxsome Therapeutics has transitioned into a commercial-stage entity with rapidly growing revenue from its central nervous system treatments...

Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome Begins Phase III Study on AXS-05 for Smoking Cessation

AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAmgen is a diversified pharmaceutical giant with high net margins. It reported nearly $8.1 billion in free cash flow for fiscal 2025...

Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run

Key PointsAxsome Therapeutics is performing well as it continues to expand its approved portfolio...

If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 26.64% on an annualized basis producing an average annual return of 40.19%. Currently, Axsome Therapeutics has a marketread more...

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030  

The FDA has already accepted the company’s application seeking the greenlight for AXS-12.


Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Bullish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Current Price	$220.75
Prev Close	$211.12
Open	$212.71
Dividend Yield	0.00%
50-Day Moving Average	$221.40
Beta	0.73
Avg. Volume	669,521.86
PE Ratio	-58.72

52-Week High	$260.19
52-Week Low	$112.90
Market Capitalization	$11.06B
EPS (Annual)	-$3.68
Price to Book	138.59
Revenue Per Employee	$690,265.95

Feed

News

Sentiment

Earnings

Fundamentals

Info

AXSM Fundamentals